These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 24720917)

  • 21. Load-Independent Systolic and Diastolic Right Ventricular Function in Heart Failure With Preserved Ejection Fraction as Assessed by Resting and Handgrip Exercise Pressure-Volume Loops.
    Rommel KP; von Roeder M; Oberueck C; Latuscynski K; Besler C; Blazek S; Stiermaier T; Fengler K; Adams V; Sandri M; Linke A; Schuler G; Thiele H; Lurz P
    Circ Heart Fail; 2018 Feb; 11(2):e004121. PubMed ID: 29449367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study.
    Mohammed SF; Borlaug BA; Roger VL; Mirzoyev SA; Rodeheffer RJ; Chirinos JA; Redfield MM
    Circ Heart Fail; 2012 Nov; 5(6):710-9. PubMed ID: 23076838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Importance of structural heart disease and diastolic dysfunction in heart failure with preserved ejection fraction assessed according to the ESC guidelines - A substudy in the Ka (Karolinska) Ren (Rennes) study.
    Persson H; Donal E; Lund LH; Matan D; Oger E; Hage C; Daubert JC; Linde C;
    Int J Cardiol; 2019 Jan; 274():202-207. PubMed ID: 30049496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of left ventricular diastolic function profile in patients with pulmonary hypertension due to heart failure with preserved ejection fraction.
    Raeisi-Giglou P; Lam L; Tamarappoo BK; Newman J; Dweik RA; Tonelli AR
    Clin Cardiol; 2017 Jun; 40(6):356-363. PubMed ID: 28026030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.
    Paulus WJ; Tschöpe C
    J Am Coll Cardiol; 2013 Jul; 62(4):263-71. PubMed ID: 23684677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delayed Repolarization Underlies Ventricular Arrhythmias in Rats With Heart Failure and Preserved Ejection Fraction.
    Cho JH; Zhang R; Kilfoil PJ; Gallet R; de Couto G; Bresee C; Goldhaber JI; Marbán E; Cingolani E
    Circulation; 2017 Nov; 136(21):2037-2050. PubMed ID: 28974519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transthyretin Cardiac Amyloidosis as Diagnosed by 99mTc-PYP Scanning in Patients with Acute Heart Failure and Preserved Ejection Fraction.
    Lo Presti S; Horvath SA; Mihos CG; Rajadhyaksha C; McCloskey V; Santana O
    Crit Pathw Cardiol; 2019 Dec; 18(4):195-199. PubMed ID: 31725511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and correlates of left ventricular diastolic dysfunction and heart failure with preserved ejection fraction in elderly community residents.
    Cui X; Zhou J; Jin X; Zhou J; Fu M; Hu K; Sun A; Ge J
    Int J Cardiol; 2017 Jan; 227():820-825. PubMed ID: 27836303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of elevated left ventricular end diastolic pressure in patients with preserved ejection fraction using cardiac magnetic resonance.
    Gao C; Tao Y; Pan J; Shen C; Zhang J; Xia Z; Wan Q; Wu H; Gao Y; Shen H; Lu Z; Wei M
    Eur Radiol; 2019 May; 29(5):2360-2368. PubMed ID: 30631923
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The differences in the relationship between diastolic dysfunction, selected biomarkers and collagen turn-over in heart failure patients with preserved and reduced ejection fraction.
    Michalski B; Trzciński P; Kupczyńska K; Miśkowiec D; Pęczek Ł; Nawrot B; Lipiec P; Kasprzak JD
    Cardiol J; 2017; 24(1):35-42. PubMed ID: 27748500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sex-Related Differences in Dynamic Right Ventricular-Pulmonary Vascular Coupling in Heart Failure With Preserved Ejection Fraction.
    Singh I; Oliveira RKF; Heerdt PM; Pari R; Systrom DM; Waxman AB
    Chest; 2021 Jun; 159(6):2402-2416. PubMed ID: 33388286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition.
    Biolo A; Ramamurthy S; Connors LH; O'Hara CJ; Meier-Ewert HK; Soo Hoo PT; Sawyer DB; Seldin DC; Sam F
    Circ Heart Fail; 2008 Nov; 1(4):249-57. PubMed ID: 19808299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of clinical characteristics of cardiac amyloidosis as a potential underlying etiology in patients diagnosed with heart failure with preserved ejection fraction.
    Murat S; Cavusoglu Y; Yalvac HE; Sivrikoz IA; Kocagil S
    Kardiol Pol; 2022; 80(6):672-678. PubMed ID: 35390167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heart Rate-Induced Myocardial Ca
    Silverman DN; Rambod M; Lustgarten DL; Lobel R; LeWinter MM; Meyer M
    J Am Heart Assoc; 2020 Sep; 9(17):e017215. PubMed ID: 32856526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An altered plasma lipidome-phenome network characterizes heart failure with preserved ejection fraction.
    Jovanovic N; Foryst-Ludwig A; Klose C; da Conceicao CR; Alasfar L; Birkner T; Forslund SK; Kintscher U; Edelmann F
    ESC Heart Fail; 2024 Jun; 11(3):1553-1566. PubMed ID: 38243357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial).
    Trippel TD; Van Linthout S; Westermann D; Lindhorst R; Sandek A; Ernst S; Bobenko A; Kasner M; Spillmann F; González A; López B; Ravassa S; Pieske B; Paulus WJ; Díez J; Edelmann F; Tschöpe C
    Eur J Heart Fail; 2018 Mar; 20(3):460-470. PubMed ID: 28891228
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of a robust mouse model of heart failure with preserved ejection fraction.
    Matsiukevich D; Kovacs A; Li T; Kokkonen-Simon K; Matkovich SJ; Oladipupo SS; Ornitz DM
    Am J Physiol Heart Circ Physiol; 2023 Aug; 325(2):H203-H231. PubMed ID: 37204871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial.
    Ravassa S; Trippel T; Bach D; Bachran D; González A; López B; Wachter R; Hasenfuss G; Delles C; Dominiczak AF; Pieske B; Díez J; Edelmann F
    Eur J Heart Fail; 2018 Sep; 20(9):1290-1299. PubMed ID: 29709099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction.
    Bosch L; Lam CSP; Gong L; Chan SP; Sim D; Yeo D; Jaufeerally F; Leong KTG; Ong HY; Ng TP; Richards AM; Arslan F; Ling LH
    Eur J Heart Fail; 2017 Dec; 19(12):1664-1671. PubMed ID: 28597497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction.
    Biering-Sørensen T; Shah SJ; Anand I; Sweitzer N; Claggett B; Liu L; Pitt B; Pfeffer MA; Solomon SD; Shah AM
    Eur J Heart Fail; 2017 Aug; 19(8):1043-1052. PubMed ID: 28322009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.